ABCG2 and breast cancer: Furthermore, the following experiments demonstrated that the delivery of a specific inhibitor targeting miR-221-3p lead to reduced drug resistance of BC cells to ADR, suppressed cell viability and promoted cell apoptosis, as evidenced by diminished levels of MDR1, BCRP, and Bcl-2 along with elevated Bax levels.